BTIG Downgrades Integra Lifesciences to Sell, Announces $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman has downgraded Integra Lifesciences (NASDAQ:IART) from Neutral to Sell and set a price target of $22.
July 30, 2024 | 9:49 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BTIG analyst Ryan Zimmerman downgraded Integra Lifesciences from Neutral to Sell and set a price target of $22.
The downgrade from Neutral to Sell and the announcement of a $22 price target by BTIG is likely to negatively impact Integra Lifesciences' stock price in the short term. Such downgrades typically lead to selling pressure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100